New oral anticoagulant drugs

Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the mos...

Full description

Saved in:
Bibliographic Details
Published in:Revista medíca de Chile 2011-10, Vol.139 (10), p.1347-1355
Main Authors: Berkovits, Alejandro, Aizman, Andrés, Zúñiga, Pamela, Pereira, Jaime, Mezzano, Diego
Format: Article
Language:Spanish
Subjects:
Administration, Oral
Anticoagulants - classification
Factor Xa Inhibitors
Humans
Thrombin - antagonists & inhibitors
Vitamin K - antagonists & inhibitors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin.
ISSN:0034-9887
0717-6163
DOI:10.4067/S0034-98872011001000016